Receptos (NASDAQ: RCPT) closed Monday just short of a 52-seek high after an analyst suggested the drug development company could become a takeover candidate.
Receptos is developing drugs for a range of immune system disorders including its...
Billing it as the most important new innovation in the interferon drug class in a decade, Biogen Idec nailed down the FDA's approval of Plegridy, a new multiple sclerosis drug that patients can easily inject themselves with once every two weeks.
(MedPage Today) -- A pegylated form of interferon-beta-1a (Plegridy) that can be administered once every 2 weeks in patients with relapsing multiple sclerosis was approved by the FDA, its manufacturer said.
Idec (NASDAQ: BIIB) announced that the U.S. Food and Drug
Administration (FDA) has approved PLEGRIDYTM (peginterferon
beta-1a), a new treatment for people with relapsing forms of multiple
Dude, where’s my car? Back in the garage because you took an Uber rather than driving high. At least that’s the idea behind leading “Yelp for marijuana” service WeedMaps and Colorado pot shop The Clinic partnering with Uber. Each time a...
(MedPage Today) -- Recent studies linked vitamin D deficiency with dementia risk and multiple sclerosis with intestinal microbiome activity, and a prostaglandin receptor may be a viable drug target in ALS.
For Biogen Idec's second quarter, multiple sclerosis star Tecfidera blew analysts' estimates out of the water, as it's been wont to do. But it wasn't Tecfidera alone that helped the Massachusetts biotech trounce sales estimates by about $250 million.
WASHINGTON (dpa-AFX) - Alkermes plc (ALKS) Thursday said it has begun its
phase 1 clinical trial of ALKS 8700, an investigational monomethyl fumarate
molecule, for the treatment of multiple sclerosis. The double -blind study will
Biogen Idec (NASDAQ: BIIB) moved up a bit after a Deutsche Bank analyst on Wednesday talked up prospects for one of its multiple sclerosis drug candidate.
If the drug gets marketing approval "the stock could move up by $30 to $100 in a single...
Oops! Unable to complete your request. Please refresh your browser.